Prosigna Breast ROR Test For Providers

The Prosigna Breast Risk of Recurrence test provides valuable information to help doctors and their patients with breast cancer make more informed and confident personalized treatment decisions. The test is indicated for patients with early-stage breast cancer that are hormone-receptor positive (HR+) prior to any non-surgical treatments.

PAM50 is the well-known and established 50-gene classifier that divides breast cancer into four intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, and Basal-like. Each subtype is associated with distinct biological behaviors and responses to treatment. A core component of the Prosigna Breast Risk of Recurrence test is the gene expression analysis of the subtypes combined with clinical pathological information (tumor size, nodal status, proliferation score). This combination provides an accurate, reliable ROR score, 10-year probability of distant recurrence, and prediction of chemotherapy benefit.

The Prosigna Breast Risk of Recurrence test provides more comprehensive information than traditional testing approaches and more accurate ROR (Risk of Recurrence) information than other similar tests. It is the only breast cancer test based on the PAM50 genomic classifier that is used to determine the intrinsic subtype and enable a more accurate assessment of tumor gene expression patterns.

Only the Prosigna Breast Risk of Recurrence test considers the standard tumor information along with the intrinsic subtype and proliferation score in a single test.

The Prosigna Breast Risk of Recurrence test report contains results and relevant, interpretive information specific to each patient, enabling clinicians to provide a personalized and precise treatment plan.

The Prosigna Breast Risk of Recurrence test reports include key pieces of information:

• Risk of Recurrence (ROR) Score
• 10-year probability of distance recurrence (with 5 years of endocrine therapy)
• Chemotherapy benefit prediction
• Intrinsic Subtype (Luminal A, Luminal B, HER2-enriched, Basal-like)
• Proliferation score

To help establish how likely it is that a patient’s cancer will recur, the Prosigna test assesses the RNA expression of the PAM50 based genomic classifier to determine the intrinsic subtype. The test then factors both the proliferation score and tumor size to calculate a single Risk of Recurrence (ROR) score. The Prosigna ROR score is combined with the patient’s nodal status to determine the likelihood that the breast cancer will return in the next 10 years, which can help doctors and their patients potentially rule out unnecessary treatment.